PMID- 36275784
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20221101
IS  - 1179-1322 (Print)
IS  - 1179-1322 (Electronic)
IS  - 1179-1322 (Linking)
VI  - 14
DP  - 2022
TI  - A Real-World Study of Optimal Treatment with Anlotinib First-Line Therapy in 
      Advanced Hepatocellular Carcinoma.
PG  - 3037-3046
LID - 10.2147/CMAR.S379911 [doi]
AB  - PURPOSE: To observe the efficacy and safety of anlotinib as a first-line 
      treatment for patients with advanced hepatocellular carcinoma (aHCC) in a 
      real-word environment, explore the optimal treatment regimen for patients with 
      aHCC using anlotinib as a first-line treatment. PATIENTS AND METHODS: Data from 
      62 patients with aHCC who received anlotinib single-drug first-line therapy 
      between February 2019 and November 2021. Patients received anlotinib monotherapy, 
      which may be interrupted or discontinued or changed in the event of unacceptable 
      or severe adverse events (AEs) or failure to inhibit tumor progression. The 
      primary endpoint was progression-free survival (PFS) and the secondary endpoints 
      were objective response rate(ORR), disease control rate (DCR), overall survival 
      (OS), and safety. RESULTS: Among the 62 patients, in the best overall response 
      assessment, there were 12 with complete response (CR; 19.4%), 17 with partial 
      response (PR; 27.4%), 25 with stable disease (SD; 40.3%), and 8 with progressive 
      disease (PD; 14.5%). The ORR and DCR were 46.8% and 87.1%, respectively. Among 
      the 11 patients who received tyrosine kinase inhibitors (TKIs) combined with 
      programmed death 1 (PD-1) inhibitors after disease progression, three (27.3%) had 
      CR, one (9.1%) had PR, three (27.3%) had SD, and four (36.4%) had PD. Therefore, 
      the ORR and DCR were 36.4% and 63.6%, respectively. The median PFS for anlotinib 
      monotherapy was 7.37 months (95% confidence interval [CI]: 5.88-8.86) and the 
      median OS did not reach. AEs occurred in 95.2% of patients during anlotinib 
      monotherapy, with the most common being thrombocytopenia (51.6%). The incidence 
      of grade >/=3 AEs was 38.7%. CONCLUSION: Anlotinib is effective and well-tolerated 
      as a first-line treatment for patients with aHCC. Treatment with TKIs and PD-1 
      inhibitors after disease progression has also shown preliminary efficacy and 
      safety; therefore, sequential therapy with anlotinib-TKIs and PD-1 inhibitors may 
      be an effective treatment for patients with aHCC.
CI  - (c) 2022 Li et al.
FAU - Li, Qingqing
AU  - Li Q
AUID- ORCID: 0000-0001-9631-1441
AD  - Department of Infectious Diseases, The First Affiliated Hospital of Zhengzhou 
      University, Zhengzhou city, People's Republic of China.
FAU - Su, Tong
AU  - Su T
AUID- ORCID: 0000-0003-4552-6594
AD  - Department of Medical, The Third Affiliated Hospital of Zhengzhou University, 
      Zhengzhou city, People's Republic of China.
FAU - Zhang, Xu
AU  - Zhang X
AD  - Department of Hepatobiliary Pancreatic Surgery, Zhengzhou University People's 
      Hospital, Henan Provincial People's Hospital, Zhengzhou city, People's Republic 
      of China.
FAU - Pan, Yanfeng
AU  - Pan Y
AUID- ORCID: 0000-0002-2438-4016
AD  - Department of Infectious Diseases, The First Affiliated Hospital of Zhengzhou 
      University, Zhengzhou city, People's Republic of China.
FAU - Ma, Shengli
AU  - Ma S
AUID- ORCID: 0000-0002-8327-292X
AD  - Department of Infectious Diseases, The People's Hospital of Yongcheng, Yongcheng 
      city, People's Republic of China.
FAU - Zhang, Lu
AU  - Zhang L
AUID- ORCID: 0000-0002-1567-7773
AD  - Department of Infectious Diseases, The People's Hospital of Yongcheng, Yongcheng 
      city, People's Republic of China.
FAU - Zhang, Xianqiang
AU  - Zhang X
AUID- ORCID: 0000-0002-5430-5198
AD  - Department of Infectious Diseases, The First Affiliated Hospital of Zhengzhou 
      University, Zhengzhou city, People's Republic of China.
FAU - Gao, Xiaojuan
AU  - Gao X
AUID- ORCID: 0000-0003-2707-2381
AD  - Department of Infectious Diseases, The First Affiliated Hospital of Zhengzhou 
      University, Zhengzhou city, People's Republic of China.
LA  - eng
PT  - Journal Article
DEP - 20221020
PL  - New Zealand
TA  - Cancer Manag Res
JT  - Cancer management and research
JID - 101512700
PMC - PMC9580834
OTO - NOTNLM
OT  - anlotinib
OT  - hepatocellular carcinoma
OT  - real world
OT  - sequential therapy
COIS- The authors declare that they have no competing interests.
EDAT- 2022/10/25 06:00
MHDA- 2022/10/25 06:01
PMCR- 2022/10/20
CRDT- 2022/10/24 04:05
PHST- 2022/06/24 00:00 [received]
PHST- 2022/09/29 00:00 [accepted]
PHST- 2022/10/24 04:05 [entrez]
PHST- 2022/10/25 06:00 [pubmed]
PHST- 2022/10/25 06:01 [medline]
PHST- 2022/10/20 00:00 [pmc-release]
AID - 379911 [pii]
AID - 10.2147/CMAR.S379911 [doi]
PST - epublish
SO  - Cancer Manag Res. 2022 Oct 20;14:3037-3046. doi: 10.2147/CMAR.S379911. 
      eCollection 2022.